Occlusive Retinal Vasculitis After Aflibercept 8mg Injection for Wet Macular Degeneration
Open Access
- 2 April 2025
- journal article
- case report
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 20 (3) , 397-400
Abstract
Purpose: To describe a case of occlusive retinal vasculitis (ORV) following intravitreal aflibercept 8mg injection for wet macular degeneration. Methods: Retrospective, interventional case report Results: A 72-year-old female presented with classic ORV 11 days after intravitreal aflibercept 8mg injection in her left eye for wet macular degeneration. Visual acuity (VA) declined from 20/30 to 20/400. Laboratory investigations including Gram stain and cultures of vitreous aspirate, studies for infectious and non-infectious uveitis and hypercoagulable state were all negative. Oral prednisone, sub-Tenon’s triamcinolone acetonide (STTA), intravitreal dexamethasone and antibiotic injections, and topical steroids resulted in visual and anatomic improvement. ORV recurred when prednisone was tapered to 10mg/day and was controlled with additional STTA, oral solumedrol, and a 0.18mg fluocinolone acetonide implant. Subsequently exudation from wet macular degeneration recurred and responded to intravitreal faricimab with recovery to 20/30. Conclusions: ORV is a rare complication of some intravitreal anti-VEGF medications and infectious causes of endophthalmitis. It can be managed with aggressive steroid treatment for an excellent visual outcome in some cases, although the disease may be chronic or recurrent.Keywords
This publication has 10 references indexed in Scilit:
- Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degenerationJapanese Journal of Ophthalmology, 2024
- Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trialThe Lancet, 2024
- Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular DegenerationJAMA Ophthalmology, 2023
- Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with BrolucizumabOphthalmology, 2021
- Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab TreatmentOphthalmology Retina, 2021
- Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative reviewInternational Journal of Retina and Vitreous, 2021
- Differing Risks of Occlusive Retinal Vasculitis with Concurrent Intraocular Inflammation Among Intravitreal Antivascular Endothelial Growth Factor TherapiesRetina, 2020
- Efficacy and Safety of Abicipar in Neovascular Age-Related Macular DegenerationOphthalmology, 2020
- HEMORRHAGIC VASCULITIS AND RETINOPATHY HERALDING AS AN EARLY SIGN OF BACTERIAL ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTIONRETINAL Cases & Brief Reports, 2019
- Postmarketing Analysis of Aflibercept-Related Sterile Intraocular InflammationJAMA Ophthalmology, 2015